Jensen Thomas 4
4 · Allarity Therapeutics, Inc. · Filed May 14, 2026
Research Summary
AI-generated summary of this filing
Allarity (ALLR) CEO Jensen Thomas Receives Award of 200,000 RSUs
What Happened
- Jensen Thomas, Chief Executive Officer of Allarity Therapeutics, was granted 200,000 restricted stock units (RSUs) on January 28, 2026. The grant is reported as an acquisition (Award/Grant, code A) at $0.00 per share (total reported value $0 on the Form 4).
Key Details
- Transaction date: January 28, 2026; Filing date: May 14, 2026 (the Form 4 appears to have been filed late).
- Grant size and price: 200,000 RSUs @ $0.00 (reported acquisition value $0).
- Shares owned after transaction: Not disclosed on this Form 4.
- Footnote: RSUs vest in equal one-third installments on the first, second, and third anniversaries of the grant, subject to Thomas’s continued relationship with the company.
- Transaction code: A (award/grant).
Context
- This was a non-cash equity award, not a purchase or sale. RSU grants are common executive compensation and typically vest over time; they do not represent immediate cash proceeds or a market-direction signal. The late filing delays public disclosure of the grant.
Insider Transaction Report
Form 4
Transactions
- Award
Common Stock
[F1]2026-01-28+200,000→ 596,734 total
Footnotes (1)
- [F1]The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
Signature
/s/ Thomas Jensen|2026-05-14